High Purity API CAS 80382-23-6 Loxoprofen Sodium, Loxoprofen Sodium
Features
We serve our customers with the business philosophy of honesty, innovation, speed and win-win, continuously reduce product costs and improve quality, so as to make our CAS: 29097-12-9, 1,2,3-Trifluoro-5-[trans-4-[2-(trans-4-propylcyclohexyl)ethyl]cyclohexyl]benzene, 6-bromo-2-methyl-4-phenylmethoxy-1H-benzimidazole more competitive in the international market. Now we have established steady and long business relationships with customers from numerous countries. We thank new and old customers for their trust with the best products, the best quality, the lowest price, and the most complete service.
A non-selective nonsteroidal anti-inflammatory drug (NSAID) that has been effective in reducing atherosclerosis in mice by reducing inflammation. It becomes active after metabolism in the body and inhibits the activation of cyclooxygenase.
Product Details:
Name: loxoprofen sodium hydrate
Synonyms:
Loxoprofen sodium;
cs-600;
loxoprofensodiumdihydrate;
Loxoprofen sodiuM hydrate;
LOXOPROFEN NA;
SodiuM Loxoprofen;
Loxonin;
Unastin;
sodium salt of Loxoprofen;
CAS: 80382-23-6
EINECS: 1806241-263-5
MF: C15H17NaO3
MW: 268.28300
Density: N/A
BP: 417.9ºCat 760 mmHg
MP: N/A
FP: 220.7ºC
Purity: 95%+
Storage condition: Store in a cool, dry place. Store in a tightly closed container.
Stability: Stable under normal temperatures and pressures.
Package: 5g, 25g, 100g, 500g, 1kg, 25kg
Application: Used as an anti-inflammatory and analgesic drug
We adhere to the market-oriented, technology-centric, service-oriented policy, and the concept of achieving customers and creating value models to meet customer needs with various High Purity API CAS 80382-23-6 Loxoprofen Sodium, Loxoprofen Sodium. With the company’s integrity, strength and product quality stability, timely delivery, we have deeply won the recognition and trust of customers around the world. Our company with excellent products, preferential prices, high-quality service to all users the greatest satisfaction, and look forward to working with all people of insight to seek common development, and continue to create brilliant.